Opus Genetics (IRD) Net Cash Flow (2010 - 2026)
Opus Genetics (IRD) posted quarterly Net Cash Flow of $14.9 million for Q1 2026, up 29.61% year-over-year from $11.5 million in Q1 2025, and up 4.15% quarter-over-quarter from $14.3 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Net Cash Flow (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Net Cash Flow for 17 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 29.61% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $18.2 million (up 438.37% YoY), while the FY2025 annual figure was $14.8 million, up 173.19% from the prior year.
- Net Cash Flow climbed to $14.9 million in Q1 2026 per IRD's latest filing, from $14.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $28.8 million in Q4 2022 and bottomed at -$9.4 million in Q2 2025.
- Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of -$2.2 million in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow soared 1160.03% — and 2024, when it tumbled 681.6%.
- Opus Genetics' Net Cash Flow stood at $28.8 million in 2022, then tumbled by 71.68% to $8.2 million in 2023, then slumped by 177.43% to -$6.3 million in 2024, then surged by 326.21% to $14.3 million in 2025, then rose by 4.15% to $14.9 million in 2026.
- Business Quant data shows IRD's Net Cash Flow at $14.9 million in Q1 2026, $14.3 million in Q4 2025, and -$1.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 28.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.95 Mn |
| Mar 31, 2026 | 14.87 Mn |
| Dec 31, 2025 | 14.28 Mn |
| Sep 30, 2025 | -1.61 Mn |
| Jun 30, 2025 | -9.36 Mn |
| Mar 31, 2025 | 11.47 Mn |
| Dec 31, 2024 | -6.31 Mn |
| Sep 30, 2024 | -4.78 Mn |
| Jun 30, 2024 | -5.75 Mn |
| Mar 31, 2024 | -3.34 Mn |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 989,000.00 |
| Mar 31, 2023 | -3.65 Mn |
| Dec 31, 2022 | 28.78 Mn |
| Sep 30, 2022 | -3.17 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | -5.29 Mn |
| Dec 31, 2021 | 2.28 Mn |
| Sep 30, 2021 | -1.98 Mn |